And there was also no difference in survival between the PD-L1 inhibitor group and the PD-1 inhibitor group in the comparison of different ICIs types.<h4>Conclusions</h4>Continuation of immunotherapy after standard first-line immunotherapy plus chemotherapy can improve survival in patients with ES-SCLC. The gene discussed is CD274; the disease is small cell lung carcinoma.